MET and renal cell carcinoma: Among the novel small inhibitors, cabozantinib, a MET, RET, and VEGFR2 inhibitor, has been reported to be effective in radioresistant MET-mutated brain metastases from renal cell carcinoma [53] and to show rapid intracranial response in crizotinib-resistant MET-exon14 positive NSCLC [54].